thiocolchicoside
Small moleculeexperimental
Thiocolchicoside is a muscle relaxant with anti-inflammatory and analgesic effects. Its mechanism of action is unknown, but it is believed to act via antagonism of nicotinic acetylcholine receptors (nAchRs). However, it also appears to be a competitive antagonist of GABAA and glycine receptors. As such, it has powerful convulsant activity and should not be used in seizure-prone individuals. — Wikipedia
Clinical trial activity
7 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
1
Phase 4
4
Earliest trial started Dec 1, 2004 (NCT00917436)
Timeline
Indications
Approved for
Mechanism of action
- GABA-A receptor alpha-1/beta-3ANTAGONIST
GABA-A receptor alpha-1/beta-3 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COc1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)cc2c(c1OC)-c1ccc(SC)c(=O)cc1C(NC(C)=O)CC2- Mol. weight
- 563.63 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaThiocolchicoside ↗
- ChEMBLCHEMBL213907 ↗
- ChEMBLCHEMBL1705373 ↗
Also known as
- 2,14-di-(demethoxy)-2-glucosidoxy-14- methylthiocolchicine
- coltramyl
- coltramyl
- miorel
- muscoril
- myoplège
- thiocholshikoside
- thiocolchicine 2-glucoside analog
- thiocolchicine 2-glucoside analog
- thiocolchicine glycoside
- thiocolchicine glycoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
- thiocolchicoside
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06791434 | Phase 4 | Aug 30, 2024 | MIT World Peace University |
| NCT05529290 | Phase 4 | Jul 16, 2019 | Van Yuzuncu Yil University, Yuzuncu Yıl University |
| NCT05261971 | N/A | Dec 1, 2018 | Yuzuncu Yıl University |
| NCT04110119 | Phase 2 | Oct 1, 2018 | Istanbul Medipol University |
| NCT00679146 | Phase 3 | Apr 1, 2008 | Sanofi |
| NCT00272532 | Phase 4 | Apr 1, 2005 | Sanofi |
| NCT00917436 | Phase 4 | Dec 1, 2004 | Sanofi |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sanofi | For profit | 3 | 3 | 2 | 2004 |
| Yuzuncu Yıl University | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Istanbul Medipol University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| MIT World Peace University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Van Yuzuncu Yil University | Academic/Hospital | 1 | 0 | 1 | 2019 |
5 organizations
Page 1 / 1